SCHEMBL17229250

SCHEMBL17229250

O=C(CCc1ccccc1)NCc1ccc(Cl)cc1

nearest known ligand 0.83

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PLAAT3 P53816 2/20 0.73
PLAAT5 Q96KN8 2/20 0.73
PLAAT2 Q9NWW9 2/20 0.73
PLAAT4 Q9UL19 2/20 0.73
ALDH1A1 P00352 4/20 0.71
L3MBTL1 Q9Y468 1/20 0.71
TRPV1 Q8NER1 3/20 0.68
MEN1 O00255 4/20 0.66
KMT2A Q03164 4/20 0.66
ERCC1 P07992 1/20 0.64
ERCC4 Q92889 1/20 0.64
GAA P10253 1/20 0.62
HPGD P15428 2/20 0.60
LMNA P02545 2/20 0.60
CYP1A2 P05177 1/20 0.60
CYP3A4 P08684 1/20 0.60
CYP2C9 P11712 1/20 0.60
CYP2C19 P33261 1/20 0.60
SLC6A9 P48067 1/20 0.59
SLC6A5 Q9Y345 1/20 0.59

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1661081 0.90 TRPV1 (0.76) ALDH1A1L3MBTL1TRPV1MEN1KMT2A
SCHEMBL17372465 0.87 PLAAT3 (0.60) PLAAT3PLAAT5PLAAT2PLAAT4ALDH1A1
SCHEMBL1894742 0.85 TRPV1 (0.82) ALDH1A1L3MBTL1TRPV1MEN1KMT2A
SCHEMBL11269450 0.85 TRPV1 (0.82) ALDH1A1L3MBTL1TRPV1MEN1KMT2A
SCHEMBL8792470 0.85 ALDH1A1 (0.71) ALDH1A1L3MBTL1TRPV1MEN1KMT2A
SCHEMBL13402006 0.85 SGMS1 (0.75) ALDH1A1GAA
SCHEMBL25046063 0.84 ALDH1A1 (0.71) PLAAT3PLAAT5PLAAT2PLAAT4ALDH1A1
SCHEMBL29171580 0.84 ALDH1A1 (0.71) PLAAT3PLAAT5PLAAT2PLAAT4ALDH1A1
SCHEMBL1567314 0.84 SELL (0.69) ALDH1A1L3MBTL1TRPV1MEN1KMT2A
SCHEMBL29171592 0.84 L3MBTL1 (0.71) ALDH1A1L3MBTL1TRPV1MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9757375-B2 Compounds that inhibit human DNA ligases and methods of treating cancer UNIVERSITY OF MARYLAND, BALTIMORE (US) 2017-09-12 US disclosed
US-9757375-B2 Compounds that inhibit human DNA ligases and methods of treating cancer UNIVERSITY OF MARYLAND, BALTIMORE (US) 2017-09-12 US disclosed
US-20150313898-A1 COMPOUNDS THAT INHIBIT HUMAN DNA LIGASES AND METHODS OF TREATING CANCER NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2015-11-05 US disclosed
US-20150313898-A1 COMPOUNDS THAT INHIBIT HUMAN DNA LIGASES AND METHODS OF TREATING CANCER NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2015-11-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150313898-A1 COMPOUNDS THAT INHIBIT HUMAN DNA LIGASES AND METHODS OF TREATING CANCER LIG1, LIG4, LIG3 PLAAT3 2944/4885PLAAT5 2141/4885PLAAT2 2817/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.